Sure. In the United Kingdom, when the data protection period came into play through the European Union, and even slightly before that in terms of the U.K. government's recognition that in order to have sustainable health care, people needed to be more involved in their own health care, they took the very positive approach to prospectively look at all of these very old prescription drugs that we've had for many years. They kind of knew the drugs were well characterized in terms of their safety and their efficacy. Which ones could they prospectively move into self-care status?
To do that the government requires research to show that something could be used in the conditions of a consumer going and talking to a pharmacist rather than having to go through a physician's service to make sure that everything is well directed. They could actually use it more on their own, with supportive care from pharmacies and nurse practitioners, and so on. So there was a lot of data.
That has resulted in a very long list, over time, of products that have been moved off prescription status and into self-care status. The 96% number that I referred to reflects the fact that Canada has followed along. In other words, we have many of the switches now that they had in Europe. But it has taken us at least seven years, on average, to make that similar move.